標(biāo)題: Titlebook: Cancer Drug Safety and Public Health Policy; A Changing Landscape Charles Bennett,Courtney Lubaczewski,Bartlett With Book 2022 The Editor(s [打印本頁(yè)] 作者: DART 時(shí)間: 2025-3-21 16:49
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy影響因子(影響力)
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy被引頻次
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy被引頻次學(xué)科排名
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy年度引用
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy年度引用學(xué)科排名
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy讀者反饋
書(shū)目名稱(chēng)Cancer Drug Safety and Public Health Policy讀者反饋學(xué)科排名
作者: 展覽 時(shí)間: 2025-3-21 21:47
Book 2022nalysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety作者: 高興一回 時(shí)間: 2025-3-22 03:17 作者: 充滿(mǎn)裝飾 時(shí)間: 2025-3-22 06:28 作者: 慢跑 時(shí)間: 2025-3-22 09:18 作者: nocturnal 時(shí)間: 2025-3-22 16:18 作者: nocturnal 時(shí)間: 2025-3-22 17:17
https://doi.org/10.1007/978-3-540-87866-7 Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(08):905–907. .). Prevailing opinion suggests that low reporting rates reflect time constraints.作者: 慢跑 時(shí)間: 2025-3-22 21:34 作者: chalice 時(shí)間: 2025-3-23 04:00 作者: 預(yù)定 時(shí)間: 2025-3-23 07:05 作者: 令人悲傷 時(shí)間: 2025-3-23 11:34 作者: Champion 時(shí)間: 2025-3-23 17:06
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions,of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(08):905–907. .). Prevailing opinion作者: emission 時(shí)間: 2025-3-23 20:39
Cancer Drug Safety and Public Health Policy978-3-031-04402-1Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: 為寵愛(ài) 時(shí)間: 2025-3-24 01:49 作者: 拋物線(xiàn) 時(shí)間: 2025-3-24 06:12 作者: alcoholism 時(shí)間: 2025-3-24 07:11
978-3-031-04404-5The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 綁架 時(shí)間: 2025-3-24 12:35 作者: 滲透 時(shí)間: 2025-3-24 16:22 作者: 淺灘 時(shí)間: 2025-3-24 20:55
https://doi.org/10.1007/978-3-540-87866-7On July 25, 2017, the second largest multi-million dollar settlement was pursued with the assistance of the Department of Justice and alleging inappropriate marketing strategies utilized by the pharmaceutical industry came to an end.作者: 單純 時(shí)間: 2025-3-25 00:24
https://doi.org/10.1007/978-3-540-87866-7Translating research findings into policy is important. Health policy researchers often testify before Congressional subcommittees and provide background on health policy issues. A rarely used, but important, tool for facilitating translation of research into policy is via filing a Citizen Petition.作者: 颶風(fēng) 時(shí)間: 2025-3-25 04:37
https://doi.org/10.1007/978-3-540-87866-7More than half of all serious adverse drug reactions are identified seven years after FDA approval. One recent and unusual example involves a syndrome initially termed nephrogenic dermatopathic fibrosis, and then called nephrogenic systemic fibrosis (NSF).作者: DUST 時(shí)間: 2025-3-25 09:08
https://doi.org/10.1007/978-3-540-87866-7Progressive multifocal leukoencephalopathy (PML) is a John-Cunningham virus-related central nervous system that is rarely observed in persons treated with the anti-CD20 monoclonal antibody, rituximab.作者: Expand 時(shí)間: 2025-3-25 13:48 作者: Intend 時(shí)間: 2025-3-25 18:09
https://doi.org/10.1007/978-3-319-22792-4Adverse drug/device reactions (ADRs) serious enough to lead to box warnings on drug labels or drug withdrawals occur in about one fifth of all new molecular entities.作者: OWL 時(shí)間: 2025-3-25 20:07
Positron Annihilation Spectroscopy (PAS),The Centers for Disease Control (CDC) indicated in 2021 that it would monitor for possible post-COVID-19 vaccination coagulopathy adverse events (AEs).作者: disrupt 時(shí)間: 2025-3-26 02:05 作者: enflame 時(shí)間: 2025-3-26 08:18
Policing of Drug Safety Information Dissemination Under the False Claims Act,On July 25, 2017, the second largest multi-million dollar settlement was pursued with the assistance of the Department of Justice and alleging inappropriate marketing strategies utilized by the pharmaceutical industry came to an end.作者: Neonatal 時(shí)間: 2025-3-26 08:56 作者: parallelism 時(shí)間: 2025-3-26 14:35 作者: 推延 時(shí)間: 2025-3-26 17:29 作者: 使成核 時(shí)間: 2025-3-26 23:00 作者: THROB 時(shí)間: 2025-3-27 04:43
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions ArAdverse drug/device reactions (ADRs) serious enough to lead to box warnings on drug labels or drug withdrawals occur in about one fifth of all new molecular entities.作者: 死亡 時(shí)間: 2025-3-27 09:08
Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse EvThe Centers for Disease Control (CDC) indicated in 2021 that it would monitor for possible post-COVID-19 vaccination coagulopathy adverse events (AEs).作者: PALMY 時(shí)間: 2025-3-27 12:15 作者: daredevil 時(shí)間: 2025-3-27 14:47 作者: IRATE 時(shí)間: 2025-3-27 19:57 作者: 踉蹌 時(shí)間: 2025-3-27 23:35
https://doi.org/10.1007/978-3-540-87866-7of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(08):905–907. .). Prevailing opinion作者: parsimony 時(shí)間: 2025-3-28 03:38
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions,usly approved) biological agents (Kozlowski et al. in N Engl J Med 365:385–388, 2011). The biological epoetin accounts for $1.8 billion in drug spending annually worldwide (primarily for the treatment of anemia due to chronic kidney disease or anemia due to cancer chemotherapy.)作者: Demonstrate 時(shí)間: 2025-3-28 08:58
7樓作者: Assignment 時(shí)間: 2025-3-28 10:56
7樓作者: Commission 時(shí)間: 2025-3-28 16:47
8樓作者: Digest 時(shí)間: 2025-3-28 19:49
8樓作者: 尖牙 時(shí)間: 2025-3-29 02:39
8樓作者: 和平 時(shí)間: 2025-3-29 06:26
9樓作者: 多骨 時(shí)間: 2025-3-29 10:40
9樓作者: arboretum 時(shí)間: 2025-3-29 11:51
9樓作者: lambaste 時(shí)間: 2025-3-29 16:33
9樓作者: NEXUS 時(shí)間: 2025-3-29 21:15
10樓作者: 反應(yīng) 時(shí)間: 2025-3-30 00:13
10樓作者: 無(wú)底 時(shí)間: 2025-3-30 07:33
10樓作者: URN 時(shí)間: 2025-3-30 10:55
10樓
